IRVINE, Calif., Nov. 13, 2017 /PRNewswire/ -- Ivantis Inc., developer of the novel Hydrus® Microstent, a micro-invasive glaucoma surgical (MIGS) device designed to lower eye pressure for open ...

IRVINE, Calif., Aug. 13, 2018 /PRNewswire/ -- Ivantis, a company dedicated to developing new and innovative solutions for glaucoma, announced toda ...

The FDA approved the Hydrus microstent based on results of the global HORIZON trial involving 556 patients from 38 centers in nine countries with mild-to-moderate glaucoma having cataract surgery.

The HORIZON trial, which compared cataract surgery alone with cataract surgery in conjunction with implantation of the Hydrus Microstent (Ivantis, Inc; Irvine, California), concluded at 3 years ...

CORONADO, Calif. — The Hydrus II trial is the first randomized controlled trial to show a microinvasive glaucoma surgery device to lower IOP by more than 20% without medications statistically ...

When comparing the Hydrus with cataract surgery and cataract surgery alone, ... MD, can be reached at New York Eye Surgery Center, 1101 Pelham Parkway North, Bronx, NY 10469; ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the closing of its previously announced acquisition of ...

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery Sight Sciences, Inc. Mon, Apr 29, 2024, 8:05 ...

RELATED: Alcon pulls eye micro-stent from market after new 5-year safety data The FDA’s approval for the Hydrus device came the same month Alcon began a voluntary recall of all versions of its ...

MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing ...